Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has been diagnosed with primary open-angle glaucoma, pigmentary glaucoma, capsular glaucoma/pseudoexfoliation, or ocular hypertension
Patient has a mean (or median) IOP of \>=23 and =\<36 in at least one eye at the 0800 hours time point at the Baseline Visit.
Patient has \<5 mmHg difference in mean (or median) IOP between eyes at each time point (0800 hours, 1000 hours, and 1600 hours) at Baseline.
Patient is currently using a prescribed ocular hypotensive medication and has been on a stable dose for 30 days prior to screening, or patient is drug-naive (those who have never used or who have not used ocular hypotensive medication for at least 4 weeks prior to screening)
Patient is able to safely discontinue current ocular hypotensive medication during up to the 4-week washout period
Patient has vision corrected to 20/80 or better in each eye
Patient is willing and able to avoid wearing contact lenses from 4 weeks prior to dosing through 24 hour after final dosing
Patient is willing and able to self-administer or has an able person available on a daily basis to assist with administration of study medications
Patient is not pregnant and not planning to become pregnant during the study
Patient is male or female ≥18 of age on the day of signing the informed consent
You may not be if
Patient is unable to use study medication in the affected eye(s)
Patient has a history of inflammatory ocular surface disease or anterior or posterior uveitis in either eye
Patient has a history of retinal detachment, diabetic retinopathy, or other progressive retinal disease
Patient has experienced significant visual field loss within the last year
Patient has had intraocular surgery in either eye in the last 4 months
Patient has a history of glaucoma surgery or refractive surgery in either eye
Patient is currently taking two or more anti-glaucoma medications (except Cosopt™ or its generic formulation)
Patient has previously used tafluprost
Patient has a history of cardiovascular disorder within 6 months prior to screening
Patient has a history of bronchial asthma, wheezing, pneumonia, COPD, other pulmonary disease, or abnormal chest x-ray
Patient has a mean (or median) IOP \>36 mmHg in either eye at the Screening Visit or at any time point (0800 hours, 1000 hours, and 1600 hours) of the Baseline Visit.
Clareo Health | Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
